STRATEGIC MODELING OF PHARMACEUTICAL SECURITY OF UKRAINE
DOI:
https://doi.org/10.11603/2312-0967.2025.4.15765Keywords:
pharmaceutical security, elements of pharmaceutical security, pharmaceutical system, healthcare pharmaceutical sector, external and internal environment, TOWS strategies, strategic directionsAbstract
Introduction. The issue of pharmaceutical security (PhS) in the modern world has evolved from a narrowly specialized healthcare topic into a fundamental component of national and global security.
The aim of the work - to substantiate and develop a logically sound, internally consistent, and prioritized strategy for the development of PhS in Ukraine.
Materials and Methods. The study was based on 16 elements of PhS and 39 factors from the external and internal environment of Ukraine’s PhS. The methods applied included a systems approach, TOWS analysis, pairwise comparisons, aggregation, modeling, scenario analysis, prioritization, formalization, and generalization.
Results and Discussion. PhS was conceptualized as a multi-level system category encompassing a set of interrelated elements and functioning across three interconnected dimensions: “Subject Security,” “State and Regulation,” and “Development and Society.” Eleven TOWS strategies were formulated, grouped into four logical blocks (WT, WO, ST, SO), and aggregated into three comprehensive strategic directions with different levels of priority: critical, high, and medium. The established interrelationship between PhS elements, TOWS strategies, and strategic directions confirms the dynamic nature of pharmaceutical security as a system capable of adapting under conditions of high uncertainty. A prioritized model of strategic development of pharmaceutical security in Ukraine has been proposed, built on the logic of “survival → growth → improvement,” which integrates subject security, institutional regulation, and the strategic development of society.
Conclusion. Implementation of the proposed strategy for the development of PhS will contribute to strengthening the resilience of Ukraine’s pharmaceutical system in the long term, enhancing its adaptability to crises and threats, and creating prerequisites for sustainable development.
References
Elbe S. The pharmaceuticalisation of security: Molecular biomedicine, antiviral stockpiles, and global health security. Rev Int Stud. 2014;40(5):919-38. DOI: 10.1017/S0260210514000151. PMID: 27570356; PMCID: PMC4983762. DOI: https://doi.org/10.1017/S0260210514000151
Saxena K, Balani S, Srivastava P. The role of pharmaceutical industry in building resilient health system. Front Public Health. 2022;10:964899. DOI: 10.3389/fpubh.2022.964899. PMID: 36530653; PMCID: PMC9751196. DOI: https://doi.org/10.3389/fpubh.2022.964899
Drug Supply Chain Security Act (DSCSA). Available from: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa.
Bhanot R. The Drug Supply Chain Security Act (DSCSA) compliance in Supply Chain. JIRT. 2025;11(11):7141-2. Available from: https://ijirt.org/publishedpaper/IJIRT176602_PAPER.pdf
Reform of the EU pharmaceutical legislation. Available from: https://health.ec.europa.eu/medicinal-products/legal-framework-governing-medicinal-products-human-use-eu/reform-eu-pharmaceutical-legislation_en.
EMA. Emer Cooke, EMA’s Executive Director: 2025 Achievements in Medicine Regulation. Press Release. Dec. 19, 2025. Available from: https://www.ema.europa.eu/en/news/emer-cooke-emas-executive-director-2025-achievements-medicine-regulation.
Hromovyk BP, Pankevych OB. Rol i mistse farmatsevtych-noi bezpeky u systemi natsionalnoi bezpeky [The role and place of pharmaceutical security in the national security system]. The Odesa Medical Journal. 2024;4:78–83. DOI: https://doi.org/10.32782/2226-2008-2024-4-13 (in Ukrainian). DOI: https://doi.org/10.32782/2226-2008-2024-4-13
Pankevych OB, Hromovyk BP. Otsiniuvannia vplyvu chynnykiv zovnishnoho i vnutrishnoho seredovyshcha na farmatsevtychnu bezpeku derzhavy [Assessment of the influence of external and internal environmental factors on the pharmaceutical safety of the state]. Farmacevtičnij časopis / Pharmaceutical Review. 2025;1:57-64. DOI: https://doi.org/10.11603/2312-0967.2025.1.15106 (in Ukrainian). DOI: https://doi.org/10.11603/2312-0967.2025.1.15106
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
